Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Leslie R. Laufman"'
Autor:
Philip C. Hawley, Thomas E. Williams, Jerry T. Guy, James S. McCaughan, Leslie R. Laufman, William J Hicks, David G. Brown
Publikováno v:
Photodynamic Therapy ISBN: 9781003066897
Photodynamic Therapy
Photodynamic Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a74d0c21c40d6911e1fa6de17dafbff
https://doi.org/10.1201/9781003066897-21
https://doi.org/10.1201/9781003066897-21
Publikováno v:
The Oncologist. 12:231-242
Purpose. To evaluate the safety and efficacy of intravenous (IV) sodium ferric gluconate complex (FG), oral ferrous sulfate, or no iron to increase hemoglobin (Hb) in anemic cancer patients receiving chemotherapy and epoetin alfa. Patients and Method
Autor:
C. Kent Osborne, Said Baidas, Gabriel N. Hortobagyi, John A. Glaspy, George D. Demetri, Debasish Tripathy, Leslie R. Laufman, Roger B. Cohen, Daniel F. Hayes, Francisco J. Esteva, Eric P. Winer, Richard C. Yocum, Laura F. Hutchins, Angela DeMichele, Maura N. Dickler
Publikováno v:
Journal of Clinical Oncology. 21:999-1006
Purpose: Bexarotene is a retinoid X receptor–selective retinoid that has preclinical antitumor activity in breast cancer. We evaluated the efficacy and safety of oral bexarotene in the treatment of patients with metastatic breast cancer. Patients a
Autor:
Holly E. Laufman, Douglas Reader, Heather Meek, Leslie R. Laufman, C. H. Spiridonidis, Sanjay Yadav
Publikováno v:
Community Oncology. 4:561-563
Autor:
C. Harris Spiridonidis, Leslie R. Laufman, D. Jeffrey Gray, Jacqueline J. Jones, Donn C. Young, Chuck C. Cho
Publikováno v:
Cancer. 78:2070-2077
BACKGROUND. In patients with advanced esophageal adenocarcinoma, the efficacy and palliative role of systemic chemotherapy are not well defined. The primary objective of this Phase II trial was to evaluate the antitumor activity and toxicity of a mul
Autor:
Eugene May, Thomas A. Nims, Leslie R. Laufman, E. Christopher Ellison, James S. McCaughan, C. Harris Spiridonidis, Jerry T. Guy, Jacqueline J. Jones, Thomas E. Williams, William J. Hicks
Publikováno v:
The Annals of Thoracic Surgery. 62:1005-1010
Background. We wanted to determine factors affecting survival rates of benefits to, and complications in patients with esophageal cancer treated with photodynamic therapy. Methods. From 1982 to January 1994, we used photodynamic therapy to treat 77 p
Autor:
Leslie R. Laufman, Bernard L. Zidar, A R N Kathy Stydnicki, William J. Hicks, Jerry T. Guy, Chuck C. Cho, C. Harris Spiridonidis, Mark L Segal, Donn C. Young, Judith W. Noltimier
Publikováno v:
Cancer. 75:1586-1593
Background. The assessment of treatment efficacy in nonsmall cell lung cancer (NSCLC) is limited by the lack of a clear association between clinical response and survival. The prognostic usefulness of treatment-induced tumor-marker declines in NSCLC
Autor:
Sandrine Marreaud, Eric Winquist, Joaquim Bellmunt, Sandra Collette, Hans von der Maase, Richard Sylvester, Graham M. Mead, Gedske Daugaard, Andreas Boehle, Leslie R. Laufman, Derek Raghavan, Luis Paz-Ares, Ronald de Wit, Maria De Santis, Iwona Skoneczna, Christine Chevreau
Publikováno v:
Journal of Clinical Oncology, 30(10), 1107-1113. American Society of Clinical Oncology
Purpose The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5698d00924801a628c4a7b5d3b4254
https://europepmc.org/articles/PMC3341152/
https://europepmc.org/articles/PMC3341152/
Autor:
Virginia Rhodes, C. Harris Spiridonidis, Leslie R. Laufman, Kelly Wallace, Karen Rossi, Jacqueline J. Jones
Publikováno v:
Cancer investigation. 22(3)
This study was designed to define the maximum tolerated dose of pegylated liposomal doxorubicin (Doxil) and multiday vinorelbine (VNB), without and with prophylactic filgrastim, and to identify antineoplastic effect.Patients with resistant cancers we
Publikováno v:
Clinical lung cancer. 1
Both docetaxel and gemcitabine are active against chemotherapy-pretreated non small-cell lung cancer (NSCLC). We previously demonstrated that weekly gemcitabine can be safely combined with monthly docetaxel with promising antineoplastic activity. In